Max
06-03-2002, 10:03 AM
Dr. Lawrence F. Marshall Joins Board of Pharmos Corporation
ISELIN, N.J., June 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS; Nasdaq Europe: PHRM) today announced the appointment of Lawrence F. Marshall, M.D. to fill a vacant seat on the Company's Board of Directors. Dr. Marshall, an internationally recognized neurosurgeon and opinion leader in the field, is currently Professor and Chair of the Division of Neurological Surgery at the University of California, San Diego Medical Center. Dr. Marshall brings to Pharmos a wealth of leadership and experience in scientific and clinical research as well as in drug development, especially in the treatment of traumatic brain injury (TBI) and other conditions and diseases of the brain and central nervous system.
"Dr. Marshall's extensive experience makes him an invaluable addition to our board," said Haim Aviv, Ph.D., Chairman and CEO. "In particular, his comprehensive understanding of traumatic brain injury -- including current market needs and priorities from a clinical perspective -- will help us meet important strategic goals."
Dr. Marshall's 30-year career as a scientist and neurosurgeon has been at the forefront in the search for new and better treatment measures to improve patient outcome. He has been principal investigator or co-investigator in over two dozen preclinical and clinical trials primarily relating to head and spinal cord injury, including projects funded by the National Institutes of Health, the Insurance Institute for Highway Safety, and several large pharmaceutical companies. Results of research undertaken by Dr. Marshall, which cover a wide range of issues related to TBI and other conditions of the brain, have been published in dozens of scientific journals. Among the numerous board, committee, editorial and other positions Dr. Marshall has held or holds are board and committee memberships with the American Brain Injury Consortium, the National Head Injury Foundation, the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. Dr. Marshall is the recipient of many distinguished medical prizes and awards.
Pharmos is currently undertaking a pivotal Phase III TBI study of dexanabinol, its first neuroprotective product under clinical development. Patients are currently being enrolled in centers in Belgium, Finland, France, Germany, Israel, Italy, the Netherlands, Spain and the UK. Upon receipt of regulatory approvals, enrollment of patients will commence in up to seven additional international countries, including the US. Enrollment of approximately 860 total patients is anticipated by the end of 2003.
Pharmos discovers, develops, and commercializes novel therapeutics to treat a range of neurological disorders such as traumatic brain injury, stroke, pain, multiple sclerosis, and other CNS and peripheral neuro- inflammatory indications.
Statements made in this press release related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products and to the Company's expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.
SOURCE: Pharmos Corporation
ISELIN, N.J., June 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS; Nasdaq Europe: PHRM) today announced the appointment of Lawrence F. Marshall, M.D. to fill a vacant seat on the Company's Board of Directors. Dr. Marshall, an internationally recognized neurosurgeon and opinion leader in the field, is currently Professor and Chair of the Division of Neurological Surgery at the University of California, San Diego Medical Center. Dr. Marshall brings to Pharmos a wealth of leadership and experience in scientific and clinical research as well as in drug development, especially in the treatment of traumatic brain injury (TBI) and other conditions and diseases of the brain and central nervous system.
"Dr. Marshall's extensive experience makes him an invaluable addition to our board," said Haim Aviv, Ph.D., Chairman and CEO. "In particular, his comprehensive understanding of traumatic brain injury -- including current market needs and priorities from a clinical perspective -- will help us meet important strategic goals."
Dr. Marshall's 30-year career as a scientist and neurosurgeon has been at the forefront in the search for new and better treatment measures to improve patient outcome. He has been principal investigator or co-investigator in over two dozen preclinical and clinical trials primarily relating to head and spinal cord injury, including projects funded by the National Institutes of Health, the Insurance Institute for Highway Safety, and several large pharmaceutical companies. Results of research undertaken by Dr. Marshall, which cover a wide range of issues related to TBI and other conditions of the brain, have been published in dozens of scientific journals. Among the numerous board, committee, editorial and other positions Dr. Marshall has held or holds are board and committee memberships with the American Brain Injury Consortium, the National Head Injury Foundation, the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. Dr. Marshall is the recipient of many distinguished medical prizes and awards.
Pharmos is currently undertaking a pivotal Phase III TBI study of dexanabinol, its first neuroprotective product under clinical development. Patients are currently being enrolled in centers in Belgium, Finland, France, Germany, Israel, Italy, the Netherlands, Spain and the UK. Upon receipt of regulatory approvals, enrollment of patients will commence in up to seven additional international countries, including the US. Enrollment of approximately 860 total patients is anticipated by the end of 2003.
Pharmos discovers, develops, and commercializes novel therapeutics to treat a range of neurological disorders such as traumatic brain injury, stroke, pain, multiple sclerosis, and other CNS and peripheral neuro- inflammatory indications.
Statements made in this press release related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products and to the Company's expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.
SOURCE: Pharmos Corporation